Functional dyspepsia treated with WangShiBaoChiWan: a randomized, double-blind, parallel-controlled, multicenter clinical study
10.3760/cma.j.cn311367-20230907-00072
- VernacularTitle:王氏保赤丸治疗功能性消化不良的随机、双盲、平行对照、多中心临床研究
- Author:
Huiyun ZHU
1
;
Xiaoyang DONG
;
Jianguo XIAO
;
Xiangpeng HU
;
Shengbao LI
;
Jianlin REN
;
Jianghong LING
;
Guoxiong ZHOU
;
Xi CHEN
;
Xiaohua HOU
;
Shengsheng ZHANG
;
Jianting CAI
;
Duowu ZOU
;
Yanqing LI
;
Bin CHENG
;
Xiaoyan WANG
;
Zhaoshen LI
;
Yiqi DU
Author Information
1. 海军军医大学第一附属医院（上海长海医院）消化内科，上海 200433
- Keywords:
WangShiBaoChiWan;
Functional dyspepsia;
Randomized controlled trial;
Mosapride
- From:
Chinese Journal of Digestion
2023;43(12):834-840
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy and safety between WangShiBaoChiWan and mosapride in the treatment of functional dyspepsia (FD).Methods:From September 2019 to September 2020, patients with postprandial fullness and early satiation who met the Rome Ⅳ criteria for FD diagnosis were enrolled from 15 hospitals, including the First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital), Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical College. The subjects were randomly divided into WangShiBaoChiWan (experimental) group and mosapride (control) group in the ratio of 1∶1. The treatment regimens were WangShiBaoChiWan+ mosapride simulator, WangShiBaoChiWan simulator+ mosapride, respectively with a treatment period of 2 weeks. The primary efficacy outcome was the improvement rates of main symptoms before and after treatment, the secondary efficacy primary efficacy outcome was the total clinical effective rate and the change of the single symptom score. And the safety indicator included adverse events. Independent sample t-test, paired t-test and chi-square test were used for statistical analysis. Results:A total of 251 FD patients were enrolled in the full analysis set, including 124 in the experimental group and 127 in the control group; 241 FD patients were in the per-protocol analysis set, including 117 in the experimental group and 124 in the control group. The analysis of per-protocol analysis set showed that the improvement rates of the main symptoms of the experimental group and the control group were (66±29)% and (60±30)%, respectively, and the difference was not statistically significant ( P>0.05). The improvement rate of the main symptoms of the experimental group reached 117% of that of the control group, which exceeded the expected non-inferiority standard of 80%. The total clinical effective rates of the experimental group and the control group were 76.07% (89/117) and 75.81% (94/124), respectively, and the difference was not statistically significant ( P>0.05). The results of full analysis set showed that the incidence of adverse events of the experimental group and the control group was 1.62% (2/124) and 1.57% (2/127), respectively, and the difference was not statistically significant ( P>0.05). There were no serious adverse events in the two groups. Conclusion:The improvement rate of the main symptoms of WangShiBaoChiWan is not inferior to that of mosapride in the treatment of FD, and it has good safety.
